Related Experiment Videos
[Gene therapy using anticancer drug-resistance genes].
1Division of Experimental Chemotherapy, Japanese Foundation for Cancer Research, Tokyo, Japan.
Human Cell
|March 1, 2000
Summary
Drug resistance gene therapy using MDR1-bicistronic retrovirus vectors can protect bone marrow cells from chemotherapy. This approach aims to improve cancer treatment efficacy and safety by enhancing drug resistance.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Research
Context:
- Myelosuppression is a significant limitation in cancer chemotherapy, impacting treatment efficacy and patient safety.
- Drug resistance gene therapy offers a potential strategy to mitigate chemotherapy-induced toxicity.
- The human multidrug-resistance gene (MDR1) is a key candidate for conferring drug resistance in hematopoietic stem cells.
Purpose:
- To develop novel MDR1-bicistronic retrovirus vectors for enhanced drug resistance gene therapy.
- To co-express the MDR1 gene with therapeutic genes using an internal ribosome entry site (IRES).
- To improve the safety and efficacy of chemotherapy for cancer patients.
Summary:
- Constructed MDR1-bicistronic retrovirus vectors using Harvey murine sarcoma virus and picornavirus IRES.
- These vectors enable co-expression of MDR1 and a second gene, such as MGMT, for protection against specific chemotherapies.
- MDR1-bicistronic vectors can also serve as an in vivo selectable marker for enriching gene-modified cells.
Impact:
- Potential to protect bone marrow cells from combination chemotherapy, including MDR1-related agents and nitrosoureas.
- Facilitates the development of more effective and safer cancer treatment regimens.
- Enables enrichment of gene-transduced cells for therapeutic gene expression, potentially applicable to various cancers.